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http://dx.doi.org/10.1016/j.jfma.201Background/purpose: As known, long-term morphine infusion leads to tolerance. We previ-
ously demonstrated that both co-infusion and post-administration of ultra-low dose
()-naloxone restores the antinociceptive effect of morphine in morphine-tolerant rats. How-
ever, whether the mechanism of the action of ultra-low dose ()-naloxone is through opioid
receptors or not. Therefore, in the present study, we further investigated the effect of
ultra-low dose (þ)-naloxone, it does not bind to opioid receptors, on the antinociceptive ef-
fect of morphine.
Methods: Male Wistar rats were implanted with one or two intrathecal (i.t.) catheters; one
catheter was connected to a mini-osmotic pump, used for morphine (15 mg/h), ultra-low dose
(þ)-naloxone (15 pg/h), morphine plus ultra-low dose (þ)-naloxone (15 pg/h) or saline (1 ml/h)
infusion for 5 days. On day 5, either ultra-low dose (þ)-naloxone (15 pg) or saline (5 ml) was
injected via the other catheter immediately after discontinued morphine or saline infusion.ve declared no conflicts of interest exist.
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796 K.-Y. Chou et al.Three hours later, morphine (15 mg in 5 ml saline) or saline were given intrathecally. All rats
received nociceptive tail-flick test every 30 minutes for 120 minutes after morphine challenge
at different temperature (45e52C, respective).
Results: Our results showed that, both co-infusion and post-treatment of ultra-low dose
(þ)-naloxone with morphine preserves the antinociceptive effect of morphine. Moreover, in
the post administration rats, ultra-low dose (þ)-naloxone further enhances the antinociceptive
effect of morphine.
Conclusion: This study provides an evidence for ultra-low dose (þ)-naloxone as a therapeutic
adjuvant for patients who need long-term opioid administration for pain management.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Morphine is the most widely used analgesic for treating
moderate to severe pain in clinical practice. However, long-
term morphine administration induces tolerance, which
hampers its clinical use. The mechanisms postulated to
explain morphine tolerance include G protein uncoupling,1
opioid receptor internalization,2 down-regulation of opioid
receptors3,4 and glutamate transporters,5 and upregulation
of N-methyl-D-aspartate (NMDA) receptors.
6,7 It has been
suggested that spinal cord glia astrocytes and microglia
contribute to the development of morphine tolerance and
tolerance associated pain sensitization. Co-administration
of a second drug with an opioid is a strategy for
enhancing the antinociceptive effect of morphine, which
also can attenuate tolerance.4,8
Ultra-low dose ()-naloxone, had been demonstrated as
an effective adjuvant with opioids to suppress opioid
tolerance and dependence, re-initiation of the classical m-
opioid receptor-Gi protein coupling signaling was observed
in chronic morphine-treated rats.9 Ultra-low dose
()-naloxone prevents the m-opioid receptor coupling
switches from Gi to Gs protein, thus attenuating tolerance
development, possibly via naloxone binds to the C-terminal
of a scaffolding protein filamin A which interacts with the
m-opioid receptors.10 Furthermore, intrathecal co-
administration of naloxone (20 ng) with morphine (2 mg)
significantly improved the pain relief in patients with
severe chronic low back pain.11 In agreement with these
reports, we previously also demonstrated that intrathecal
co-infusion of ultra-low dose ()-naloxone with morphine,
significantly inhibited the development of tolerance in
accompanied with reduction of CSF excitatory amino acid
glutamate and aspartate concentration, suppression of
microglia activation, and down-regulation of proin-
flammatory cytokine levels in the spinal cord microglia of
chronic morphine-infused rats.12,13
On the basis of the evidence for glia cell activation
during the development of morphine tolerance and the
modulating effect of ultra-low dose naloxone on the anti-
nociceptive effect of morphine, we suggest that co-
treatment of ultra-low dose naloxone with morphine
might maintain the normal microenvironment of neuron
and glia cells, thus restores the antinociceptive effect of
morphine. In the present study, we investigated the effect
of ultra-low dose (þ)-naloxone, it does not act through
opioid receptors,14,15 on restoration of the antinociception
of morphine in morphine-tolerant rats.Methods and materials
Animal preparation and intrathecal drug delivery
The use of rats in this study conformed to the Guiding
Principles in the Care and Use of Animals of the American
Physiology Society and was approved by the National De-
fense Medical Canter Animal Care and Use Committee. Male
Wistar rats (350-400 g; Biolasco Taiwan Co., Taipei, Taiwan)
were anaesthetized with phenobarbital (65 mg/kg, intra-
peritoneally) and implanted with one or two intrathecal
catheters. The catheter was inserted via the atlantoocci-
pital membrane down to the spinal cord segments L5, L6
and S1eS3 that relative to the tail flick reflex.16 One
intrathecal catheter was connected to a mini-osmotic pump
(Alzet, Cupertino, CA) for infusion of saline (1 ml/h), or
morphine (15 mg/h; Sigma, Missouri, USA), or ultra-low dose
(þ)-naloxone (15 pg/h; generous gift from Dr. Jau-Shyong
Hong, National Institutes of Health, Research Triangle
Park, North Carolina, USA), or morphine plus ultra-low dose
(þ)-naloxone (15 pg/h) at the rate of 1 ml/h for 5 days.
After catheterization (day 0), all rats were returned to their
home cages for recovery. Each rat was housed individually
and maintained on a 12 h light/dark cycle with food and
water freely available. Rats with neurological deficits were
excluded. On day 5 after morphine tolerance developed, (i)
the morphine pluses ultra-low dose (þ)-naloxone co-
infusion rats were underwent a nociceptive tail-flick test.
(ii) In the post-treatment rats; the intrathecal catheter for
saline or morphine infusion was cut, and the rats were
intrathecally injected with saline (5 ml) or ultra-low dose
(þ)-naloxone (15 pg), and 30 min later, a single dose of
morphine (15 mg in 5 ml saline, intrathecally) was injected
and the antinociceptive effect was measured. All drugs
were delivered intrathecally in 5 ml and flushed by 8 ml of
saline. No abnormal motor function was observed in all rats
after intrathecal test drug injection (data not shown).Antinociceptive tests
Tail-flick latency, using the hot water immersion test
(52  0.25C), was measured before drug infusion and daily
after start of infusion for 5 days. The temperature of water
was controlled by Thermostatic Circular Water Bath with
thermometer. The averaged baseline tail-flick latencies of
all rats in the 52C warm-water were 2 0.25 s. A latency of
10 seconds was set as the cut-off time to avoid tail damage.
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cally) was performed after the 5-day infusion; rats were
placed in plastic restrainers for drug injection and anti-
nociception measurement. The peak antinociceptive
response tomorphine challengewas observed at 30min after
injection in our previous studies.12,17 Different temperatures
were used, 45e52C (nZ 5/each temperature), to examine
the thermal nociceptive threshold shift inmorphine-tolerant
rats and the effect of ultra-low dose (þ)-naloxone treatment
on the nociceptive effect of morphine in rats. The percent-
age of the maximal possible antinociceptive effect (% MPE)
was calculated as (maximum latency e baseline latency)/
(cut-off latency e baseline latency)  100.
Construction of intrathecal catheter
The intrathecal catheter construction was followed as our
previous study.18e20 The intrathecal catheter was con-
structed using an 8-cm polyethylene tube (0.008 inch inner
diameter, 0.014 inch outer diameter; Spectranetics, Colo-
rado springs, CO, USA) and a 3.5 cm silastic tube (Dow
Corning, Midland, MI, USA). The silastic tube was inserted
into the polyethylene tube and the joint sealed with epoxy
resin and silicon rubber. The dead space of the intrathecal
catheter was about 8 ml.
Statistical analysis
All data are presented as mean  S.E.M. The statistical
analysis was performed using SigmaStat 3.0 software
(SYSTAT Software Inc., San Jose, CA). Behavior tests were
analyzed using two-way (time and treatment) ANOVA with a
post hoc Bonferroni correction followed by subsequent one-
way ANOVA (at each time of the experiment). A significant
difference was defined as a p-value ＜0.05.
Results
Ultra-low dose (D)-naloxone co-infusion preserves
the thermal antinociceptive effect of morphine
Rats receiving intrathecal morphine (15 mg/h) infusion for
5 days developed morphine tolerance as our previousTable 1 Tail-flick latency (sec) of temperature response in diff
Sal NLX
45C 9.98  0.02 9.96  0.09
46C 9.8  0.63 9.75  0.53
47C 9.78  0.62 9.68  0.79
48C 7.72  0.5 7.52  1.2
49C 7.31  0.37 7.11  1.44
50C 5.0  0.32 5.21  1.12
51C 4.23  0.93 4.03  0.9
52C 2.05  0.07 2.25  0.17
Tail-flick latency was performed on day 5 after drug infusion. All da
**p < 0.01 compared to the saline-infusion group.
##p < 0.01 compared to the morphine-infusion group.studies (data no shown).12,13,19,21e23 On day 5, different
temperatures were used (45e52C) to examine the thermal
nociceptive threshold shift in morphine-tolerant rats and
the effect of ultra-low dose (þ)-naloxone treatment on the
nociceptive effect of morphine in rats (Table 1). As shown
in Fig. 1 chronic morphine infusion (Mo) showed a signifi-
cant decreased nociceptive temperature threshold to 50%
MPE of tail-flick latency from 50.0C to 48.56C (p ＜ 0.01,
compare with saline control group). While, co-infusion of
ultra-low dose (þ)-naloxone with morphine preserving the
50% MPE of tail-flick latency at 51.32C (p＜ 0.01, compare
with saline control and morphine groups). It suggests that
co-infusion of ultra-low dose (þ)-naloxone with morphine
prevents the morphine tolerance development and main-
tains the antinociception of morphine.Ultra-low dose (D)-naloxone restores the
antinociceptive effect of morphine in morphine-
tolerant rats
On day 5, nociceptive tolerance was developed after
continued morphine (15 mg/h) infusion. At 3 hours after
discontinuation of morphine infusion, intrathecal ultra-low
dose (þ)-naloxone (15 pg) was pretreated 30 minutes before
morphine (15 mg) challenge, then the tail-flick latency
(45e52C) was performed (Table 2), the nociceptive base-
line was 1.98  0.37 seconds. Similar to our previous study,7
morphine challenge on day 5 (Fig. 2) produced a significant
antinociceptive effect in saline-infused rats (9.95  0.2 sec;
Sal/Mo), but not in morphine-tolerant rats (0.9  0.31 sec;
Mo/Mo). As expected, ultra-low dose (þ)-naloxone (15 pg)
alone had no antinociceptive effect in either saline-infused
controls (data not shown; Sal/NLX) or morphine-tolerant
rats (2.24  0.24 sec; Mo/NLX). In contrast, ultra-low dose
(þ)-naloxone alone restored the nociceptive threshold to
the control level (p Z 0.875, compared with saline control
group). Furthermore, pretreatment of ultra-low dose
(þ)-naloxone (15 pg), before morphine challenge, signifi-
cantly restored the antinociceptive effect of morphine
(5.02  0.74 sec; Mo/NLX/Mo). Identically, pretreatment of
ultra-low dose (þ)-naloxone (15 pg) also significantly re-
stores the 50%MPE of tail-flick latency from 48.30C (Mo/Mo)
back to 52.02C (p ＜ 0.01, compare with morphine toler-
ance group). It suggests that pretreatment with ultra-lowerent-treated rats.
Mo Mo/NLX
9.83  0.41 10  0
9.15  1.01 9.95  0.17
7.33  0.8** 9.88  0.37##
5.55  0.57** 9.29  1.39##
4.91  0.9** 8.86  1.22##
3.42  0.98* 6.33  1.26##
1.963  0.56** 5.8  1.1##
1.24  0.24** 4.42  0.94##
ta points are the mean  SEM for 5 rats per group. *p < 0.05;
Figure 1 Ultra-low dose (D)-naloxone attenuated
morphine tolerance. Temperature-response curves for the
antinociceptive effect of morphine constructed from the tail-
flick test results were calculated from data on day 5 of drug
infusion. All data points are the mean SEM and averaged from
the indicated number of rats. **p< 0.01 compared to the saline-
infusion group. ##p < 0.01 compared to the morphine-infusion
group. The dashed line indicates 50% MPE. Sal Z saline;
NLX Z ultra-low dose (þ)-naloxone; Mo Z morphine;
Mo þ NLXZ morphine þ ultra-low dose (þ)-naloxone.
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threshold to the control baseline and further restores the
antinociception of morphine in morphine-tolerant rats.Discussions
This study shows that ultra-low dose (þ)-naloxone pre-
serves the antinociceptive effect of morphine both in
co-treatment and post-treatment with morphine in
morphine-tolerant rats. Moreover, co-treatment ultra-low
dose (þ)-naloxone with morphine further prevents
morphine tolerance development in rats.
Morphine is the most effective drug for pain relief.
However, repeated use of morphine induces tolerance to its
analgesic effect. The underlying mechanisms of morphine
tolerance are complex, co-administration of a second drugTable 2 Tail-flick latency (sec) of temperature response after
Sal/Sal Sal/Mo M
45C 9.99  0.02 10  0 9.
46C 9.78  0.53 10  0 8.
47C 9.67  0.60 9.99  0.01 7.
48C 7.83  0.24 9.98  0.01** 5.
49C 6.51  0.31 9.98  0.02** 4.
50C 4.80  0.12 9.98  0.02** 3.
51C 3.75  0.95 9.97  0.02** 1.
52C 1.98  0.37 9.95  0.2** 0
Tail-flick latency was performed on day 5 after morphine challenge.
**p < 0.01 compared to the saline-infusion group.
##p < 0.01 compared to the morphine-infusion group.with morphine is a strategy for enhancing the anti-
nociceptive effect and attenuating the development of
tolerance.7,21,24 Our previous studies indicated that dexa-
methasone co-infusion with morphine reduces morphine-
evoked excitatory amino acid release and downregulates
glutamate transporters GLT-1 and GLAST expression25 and
co-infusion of amitriptyline with morphine maintains the
antinociceptive efficacy of morphine by attenuation of
morphine-induced neuroinflammation19,22 and NMDA re-
ceptor NR1 subunit and PKCg expression.21 Ultra-low dose
()-naloxone, use as an effective adjuvant with opioids to
suppress opioid dependence and tolerance, it has been
shown to be associated with switches in m-opioid receptor-
G coupling and Gb/g subunit signaling in chronic morphine-
tolerant rats.9 Ultra-low dose ()-naloxone prevents the
coupling switch of Gi/s protein, thus attenuating opioid
tolerance, via regulating interaction of naloxone with C-
terminal of filamin A.10 Moreover, our recently studies also
provide evidence that ultra-low dose ()-naloxone pre-
serves the antinociceptive effect of morphine via attenu-
ation of NMDA receptor neurotransmission and suppression
of neuroinflammation in morphine-tolerant rats.12,13
Furthermore, intrathecal naloxone (20 ng) with morphine
(2 mg) has been reported to produce a dramatic improve-
ment in pain management in humans with severe chronic
low back pain.11 These results indicate that the combina-
tion of ultra-low dose ()-naloxone with morphine can
preserve the analgesic effect of morphine, possibly through
modulation of multiple signal transduction pathways.
Although the success of ultra-low dose ()-naloxone in
preventing morphine tolerance development is consistently
reported for studies in which ultra-low dose ()-naloxone
was administrated by continuous infusion,12,13 however, we
did not know whether the preventing of morphine tolerance
and anti-neuroinflammatory effect of ultra-low dose
()-naloxone was involved in the opioid receptor-mediated
signaling pathway. The present study proved the effect
was due to mechanisms not related to the opioid receptors
because (þ)-naloxone does not bind to the opioid re-
ceptors.14,15 Studies had found that both ()-naloxone and
(þ)-naloxone significantly attenuated b-amyloid peptide-
induced superoxide production in microglia cells and that
the anti-inflammatory effect of naloxone may not be
directly related to opioid receptors,26 as (þ)-naloxone,
which does not bind to opioid receptors, also had amorphine challenge in rats.
o/Mo Mo/NLX Mo/NLX/Mo
03  0.61 10.0  0 10.0  0
05  0.35** 9.75  0.12 10  0##
03  0.5** 8.58  0.33## 9.78  0.23##
50  0.53** 7.22  0.19## 8.99  0.79##
01  1.2** 5.56  0.7## 8.06  0.22##
42  0.28** 4.63  0.56## 7.03  0.66##
95  0.26** 3.54  0.89## 6.18  0.68##
.9  0.31** 2.22  0.24## 5.02  0.74##
All data points are the mean  SEM for 5 rats per group.
Figure 2 Ultra-low dose (D)-naloxone restored the anti-
nociceptive effect of morphine. Morphine’s antinociceptive
effect was examined on day 5 after intrathecal either saline
(1 ml/h) or morphine (15 mg/h) infusion. At 3 hours after
discontinuation of infusion, the rats were intrathecally injec-
ted either saline or ultra-low dose (þ)-naloxone (15 pg) 30 mi-
nutes before morphine challenge (15 mg), by which the tail-
flick latencies had returned to less than 3 seconds, then the
tail-flick latency was measured every 30 minutes for 120 mi-
nutes. Temperature-response curves for the antinociceptive
effect of morphine constructed from the tail-flick test results
were calculated from data at 60 minutes after morphine
challenge. All data points are the mean  SEM of five rats per
group. **p < 0.01 compared to the saline-infusion group.
##p < 0.01 compared to the morphine-infusion group. The
dashed line indicates 50% MPE. Sal/Sal Z saline-infusion plus
saline challenge; Sal/Mo Z saline-infusion plus morphine
challenge; Mo/Mo Z morphine-infusion plus morphine chal-
lenge; Mo/NLX Z morphine-infusion plus ultra-low dose
(þ)-naloxone pretreatment; Mo/NLX/Mo Z morphine-infusion
plus morphine challenge with ultra-low dose (þ)-naloxone
pretreatment.
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naloxone was found to reduce cocaine-induced and
amphetamine-induced hyperactivity in mice27,28. Our pre-
sent study demonstrated that 15 pg (þ)-naloxone not only
prevented morphine tolerance development but also
enhanced the antinociceptive effect of morphine in
morphine-tolerant rats. Together, these results raise the
possibility that ultra-low dose (þ)-naloxone acts by binding
to sites other than opioid receptors.
In our previous studies, we found that ultra-low dose
()-naloxone cotreatment with morphine can inhibit
neuropathic thermal hyperalgesia,20,29 which might be
through its anti-inflammatory action on the spinal cord
microglia and reinitiate the classical m-opioid receptor
and Gi-protein coupling in the pertussis toxin-induced
neuropathic pain rats. These results suggest that ultra-
low dose ()-naloxone restores the opioid signaling in
pertussis toxin-treated rats to that of normal rats, thus
reversing the antinociceptive effect of morphine via the
inhibitory m-opioid receptor/Gi-protein signal trans-
duction pathway. In our present study, ultra-low dose
(þ)-naloxone cotreatment with morphine significantprevented morphine tolerance development and further
enhanced the antinociceptive effect of morphine. More-
over, in morphine-tolerant rats, ultra-low dose
(þ)-naloxone completely recovered the tail-flick latency
to that of control baseline and further enhanced the
antinociceptive effect of morphine in morphine tolerant
rats. Our results indicate that ultra-low dose (þ)-naloxone
might regulate m-opioid receptor/Gi-protein coupling via
different mechanisms other than the opioid-mediated
actions. This study provides new evidence that ultra-low
dose (þ)-naloxone may have potential as an analgesic
adjuvant in clinical pain management, particularly for
patients who need long-term morphine treatment and
morphine-tolerant patients who require better pain
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